Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000372590

Medchemexpress LLC DDO-2213 | 2378768-36-4 | C24H27ClFN7O | 5 MG
SDP

Catalog No. 5000372590
Encompass_Preferred

DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC50 of 29 nM and a Kd value of 72.9 nM for the WDR5 protein. It selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research.

  • Orally active
  • Potent WDR5-MLL1 inhibitor
  • Selectively inhibits MLL histone methyltransferase activity
  • Inhibits proliferation of MLL translocation-harboring cells
  • Useful for MLL fusion leukemia research

Catalog No. 50-003-72590 Supplier Medchemexpress LLC Supplier No. HY1533315MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC50 of 29 nM and a Kd value of 72.9 nM for the WDR5 protein. It selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research.

  • Orally active
  • Potent WDR5-MLL1 inhibitor
  • Selectively inhibits MLL histone methyltransferase activity
  • Inhibits proliferation of MLL translocation-harboring cells
  • Useful for MLL fusion leukemia research

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.